Dedicated Booth for the Second Consecutive Year
Samsung Biologics announced on October 14 that it will participate in BioPlus-Interphex Korea 2025 (BIX 2025), the largest comprehensive pharmaceutical and biotech convention in Korea.
BIX is the largest global pharmaceutical and biotech exhibition in Korea, hosted by the Korea Biotechnology Industry Organization and organized by RX Korea. The event serves as a platform for sharing the latest technologies and industry trends, as well as exploring business partnerships through networking. This year, it will be held from October 15 to 17 at COEX in Samseong-dong, Seoul. Approximately 300 companies and over 12,000 attendees are expected to visit the venue.
Samsung Biologics will set up a dedicated booth for the second consecutive year. The booth will use wall graphics to highlight its unrivaled production capacity, which is expected to reach 1,324,000 liters by 2032, as well as showcase its end-to-end service capabilities spanning from clinical trial services (CRO) to contract manufacturing (CMO). Key features include Samsung Organoids, its contract development (CDO) platform, and next-generation modality service capabilities.
This year, the booth will prominently promote the newly launched CMO brand, ExellenS™. ExellenS represents a manufacturing framework that emphasizes equivalency and speed as core values, reflecting the company's commitment to delivering consistently high-quality pharmaceuticals to clients quickly.
On the second day of the event, October 16, a session will be held to highlight the competitiveness of Samsung Biologics' CDO services. Lee Taehee, Head of the Antibody Culture PD Team (Executive Director), will present strategies for accelerating drug development timelines, covering the process from feasibility assessment to IND submission.
During the event, Samsung Biologics will also engage in sponsorship activities to enhance brand awareness. A hanging banner will be installed at the top of the exhibition booth, and a floor banner at the bottom, to increase recognition of the company's vision and service competitiveness.
Meanwhile, Samsung Biologics has been expanding its engagement with both existing and potential clients by participating in various global conferences throughout the year. Earlier this year, the company met with a range of clients at the Bio International Convention (BioUSA) in June and BIO Japan in October. Later this month, Samsung Biologics plans to further strengthen its order intake activities by participating in CPHI Worldwide, the largest pharmaceutical and biotech conference in Europe, which will be held in Frankfurt, Germany.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
